Reciprocal autoreceptor and heteroreceptor control of serotonergic,dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents
Restricted accessResearch articleFirst published online March, 2000
Reciprocal autoreceptor and heteroreceptor control of serotonergic,dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents
The frontal cortex (FCX) plays a key role in processes that control mood, cognition and motor behaviour, functions which are compromised in depression, schizophrenia and other psychiatric disorders. In this regard, there is considerable evidence that a perturbation of monoaminergic input to the FCX is involved in the pathogenesis of these states. Correspondingly, the modulation of monoaminergic transmission in the FCX and other corticolimbic structures plays an important role in the actions of antipsychotic and antidepressant agents. In order to further understand the significance of monoaminergic systems in psychiatric disorders and their treatment, it is essential to characterize mechanisms underlying their modulation. Within this framework, the present commentary focuses on our electrophysiological and dialysis analyses of the complex and reciprocal pattern of autoand heteroreceptor mediated control of dopaminergic, noradrenergic and serotonergic transmission in the FCX. The delineation of such interactions provides a framework for an interpretation of the influence of diverse classes of antidepressant agent upon extracellular levels of dopamine, noradrenaline and serotonin in FCX. Moreover, it also generates important insights into strategies for the potential improvement in the therapeutic profiles of antidepressant agents.
Adell A, Artigas F (1999) Regulation of the release of 5-hydroxytryptamine in the median raphe nucleus of the rat by catecholaminergic afferents. Eur J Neurosci11: 2305–2311
2.
Aghajanian G K, Sprouse J S, Rasmussen K (1988) Electrophysiology of central serotonin receptor subtypes. In Sanders-Bush E (ed.), The serotonin receptors. Humana Press, Clifton, pp. 226–252
3.
Agid O, Lerer B (1999) Risperidone augmentation of paroxetine in a case of severe treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. J Clin Psychiatry60: 55–56
4.
Aizenberg D, Gur S, Zemishlany Z, Granek M, Jeczmien P, Weizman A (1997) Mianserin, a 5-HT2A/2C and [.alpha]2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol20: 210–214
5.
Andersson J L, Marcus M, Nomikos G G, Svensson T H (1994) Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal, dopaminergic system. NaunynSchmiedeberg's Arch Pharmacol349: 236–243
6.
Apter J T, Allen L A (1999) Buspirone: future directions. J Clin Psychopharmacol19: 86–93
7.
Arborelius L, Nomikos G G, Hacksell U, Svensson T H (1993) (R)-8-OH-DPAT preferentially increases DA release in the rat medial prefrontal cortex. Acta Physiol Scand148: 465–466
8.
Arnsten A F T (1997) Catecholamine regulation of the prefrontal cortex. J Psychopharmacol11: 151–162
9.
Artigas F, Romero L, de Montigny C, Blier P (1996): Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci19: 378–383
10.
Audinot V, Newman-Tancredi A, Gobert A, Rivet J-M, Brocco M, Lejeune F, Gluck L, Desposte I, Berroets K, Dekeyne A, Millan M J (1998) A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103, 691 and U 99194. J Pharmacol Exp Ther287: 1–11
11.
Audinot V, Newman-Tancredi A, Moreira C, Millan M J (1999) Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)1B and h5-HT1D receptors. Am Soc Neurosci Abstr25: 584.5
12.
Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P, Perucca E, Caputi A P (1997) Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res35: 335–339
13.
Baik J H, Picetti R, Saiardi A, Thirlet G, Dierich A, Depaulis A, Le Meur M, Borrelli E (1995) Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature377: 424–428
14.
Balon R (1993) Fluoxetine-induced sexual dysfunction and yohimbine. J Clin Psychiatry54: 161–162
15.
Bartlett E J, Brodie J D, Simkowitz P, Dewey S L, Rusinek H, Wolf A P, Fowler J S, Volkow N D, Smith G, Wolkin A, Cancro R (1994) Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am J Psychiatry151: 681–686
16.
Barton C L, Hutson P H (1999) Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: evidence for the involvement of both 5-HT1A and 5-HT1B/D autoreceptors. Synapse31: 13–19
17.
Bartoszyk G D, Hegenbart R, Ziegler H (1997) EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol322: 147–153
18.
Baumann P (1996) Pharmacokinetic–pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet6: 444–469
19.
Baxter G S (1996) Novel discriminatory ligands for 5-HT2B receptors. Behav Brain Res73: 149–152
20.
Beauregard M, Leroux JM, Bergmam S, Arzoumanian Y, Beaudoin G, Bourgoin P, Stip E (1998) The functional neuroanatomy of major depression: an fMRI study using an emotional activation paradigm. NeuroReport9: 3253–3258
21.
Beique J C, de Montigny C, Blier P, Debonnel G (1998) Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. Br J Pharmacol125: 526–532
22.
Bel N, Artigas F (1996) In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function: microdialysis studies. J Pharmacol Exp Ther278: 1064–1072
23.
Bengtsson H J, Kele J, Hjorth S (1999) Lack of evidence for indirect stimulation of 5-HT output by the novel antidepressant mirtazapine. Nordic J Psychiatry53: 84-84
24.
Bermanzohn P C, Siris S G (1992) Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Compr Psychiatry33: 221–230
25.
Berzewski H, Van Moffaert M, Gagiano C A (1997) Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol7: S37–S47
26.
Birkenhäger T K, Moleman P, Nolen W A (1995) Benzodiazepines for depression? A review of the literature. Int Clin Psychopharmacol10: 181–198
27.
Biver F, Wilker D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J (1997) Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry171: 444–448
28.
Blier P, Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychophamacol15: 217–222
29.
Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci15: 220–226
30.
Bobker D H, Williams J T (1989) Serotonin agonists inhibit synaptic potentials in the rat locus ceruleus in vitro via 5hydroxytryptamine1A and 5-hydroxytryptamine1B receptors. J Pharmacol Exp Ther250: 37–43
31.
Boess F G, Martin I L (1994) Molecular biology of 5-HT receptors. Neuropharmacology33: 275–317
32.
Bonhomme N, Esposito E (1998) Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. J Clin Psychopharmacol18: 447–454
33.
Bonhomme N, De Deurwaerdere P, Le Moal M, Spampinato U (1995) Evidence for 5-HT4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: a microdialysis study in the halothane-anesthetized rat. Neuropharmacology34: 269–279
34.
Bordet R, Thomas P, Dupuis B (1998) Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry155: 1346–1351
35.
Bös M, Jenck F, Martin J R, Moreau J-L, Sleight A J, Wichmann J, Widmer U (1997) Novel agonists of 5-HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1methylethylamines and 2-(indenol[1, 2-b]pyrrol-1methylethylamines. Improved therapeutics for obsessive compulsive disorder. J Med Chem40: 2762–2769
36.
Bosker F J, de Winter T Y, Klompmakers A A, Westenberg H G (1996) Flesinoxan dose-dependently reduces extracellular 5hydroxytryptamine (5-HT) in rat median raphe and dorsal hippocampus through activation of 5-HT1A receptors. J Neurochem66: 2546–2555
37.
Bottcher H, Andersson B, Bartoszyk G D, Devant R, Greiner H E, Hansson L, Seyfried C A, Sonesson C, Sternlöf P (1998) EMD 95750: 5-HT reuptake inhibiting and 5-HT1A antagonist properties combined in a single NCE. Am Soc Neurosci Abstr24: 438.5–438.5
38.
Boulenguez P, Peters S L, Mitchell S N, Chauveau J, Gray J A, Joseph M H (1998) Dopamine release in the nucleus accumbens and latent inhibition in the rat following micro-injections of a 5HT1B agonist into the dorsal subiculum: implications for schizophrenia. J Psychopharmacol12: 258–267
39.
Broderick P A (1997) Alprazolam, diazepam, yohimbine, clonidine: in vivo CA1 hippocampal norepinephrine and serotonin release profiles under chloral hydrate anesthesia. Prog NeuroPsychopharmacol Biol Psychiatry21: 1117–1140
40.
Broderick P A, Hope O, Jeannot P (1998) Mechanism of triazolobenzodiazepine and benzodiazepine action in anxiety and depression: behavioral studies with concomitant in vivo CA1 hippocampal norepinephrine and serotonin release detection in the behaving animal. Prog Neuro-Psychopharmacol Biol Psychiatry22: 353–386
41.
Broekkamp C L E, Leysen D, Peeters B W M M, Pinder R M (1995) Prospects for improved antidepressants. J Med Chem38: 4615–4633
42.
Brunello N (1997) Rationale for the development of noradrenaline reuptake inhibitors (NARIs). Hum Psychopharmacol13: S13–S19
43.
Burrows G D, Maguire K P, Norman T R (1998) Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry59: 4–7
44.
Cahir M, Konkel M J, Durkin M M, Wetzel J M, Branchek T A, Craig D (1998) Autoradiographic distribution of the α1D-adrenoceptor in the rat CNS. Br J Pharmacol125: 38P–38P
45.
Caldelcott-Hazard S, Morgan D G, Deleon-Jones F, Overstreet D H, Janowsky D (1991) Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories. Synapse9: 251–301
46.
Cameron D L, Williams J T (1994) Cocaine inhibits GABA release in the VTA through endogenous 5-HT. J Neurosci14: 6763–6767
47.
Cameron D L, Wessendorf M W, Willians J T (1997) A subset of ventral tegmental area neurons is inhibited by dopamine, 5hydroxytryptamine and opioids. Neuroscience77: 155–166
48.
Cappiello A, McDougle C J, Malison R T, Heninger G R, Price L H (1995) Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study. Biol Psychiatry38: 765–767
49.
Carlsson A (1975) Receptor mediated control of dopamine metabolism. In Usdin E, Bunney W E Jr (eds), Preand postsynaptic receptors, Marcel Dekker, New York, pp. 49–65
50.
Carpenter L L, Jocic Z, Hall J M, Rasmussen S A, Price L H (1999) Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry60: 45–45
51.
Cenci M A, Kalén P, Mandel R J, Björklund A (1992) Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Brain Res581: 217–228
52.
Cesana R, Ceci A, Ciprandi C, Borsini F (1993) Mesulergine antagonism towards the fluoxetine anti-immobility effect in the forced swimming test in mice. J Pharmacol Pharmacol45: 473–475
53.
Chen J, Paredes W, Van Praag H M, Lowinson J H, Gardner E L (1992) Presynaptic dopamine release is enhanced by 5-HT3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse10: 264–266
54.
Chen H Y, Lin Y P, Lee E H Y (1992) Cholinergic and GABAergic mediations of the effects of apomorphine on serotonin neurons. Synapse10: 34–43
55.
Chen N H, Reith M E A (1995) Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systematically with (±)-8-hydroxy-2-(di-n-propylamino) tetralin. J Neurochem64: 1585–1597
56.
Cheung N Y, French S J, Rattray M (1998) The localisation of gene expression of 5-HT2A, 5-HT2B and 5-HT2C receptor mRNAs in the rat brain. Am Soc Neurosci Abstr24: 436.6–436.6
57.
Chiang C, Aston-Jones G (1993) A 5-hydroxytryptamine2 agonist augments γ-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience54: 409–420
58.
Ciraulo D A, Shader R I (1990) Fluoxetine drug–drug interactions. I. Antidepressants and antipsychotics. J Clin Psychopharmacol10: 48–50
59.
Clement H W, Gemsa D, Wesemann W (1992) Serotoninnorepinephrine interactions: a voltammetric study on the effect of serotonin receptor stimulation followed in the N. raphe dorsalis and the locus coeruleus of the rat. J Neural Transm88: 11–23
60.
Cooper B R, Hester T J, Maxwell R A (1980) Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for the selective blockade of dopamine uptake in vivo. Drug Dev Res215: 127–134
61.
Coplan J D, Lydiard R B (1998) Brain circuits in panic disorders. Biol Psychiatry44: 1264–1276
62.
Cragg S J, Greenfield S A (1997) Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area and striatum. J Neurosci17: 5738–5746
63.
Craven R, Grahame-Smith D, Newberry N (1997) 5-HT2-like receptor-mediated depolarization of 5-HT-containing dorsal raphe neurones in vitro. Br J Pharmacol120: 261–261
64.
Crews F T, Smith C B (1978) Presynaptic alpha-receptor subsensitivity after long-term antidepressant treatment. Science202: 322–324
65.
Crews F T, Scott J A, Shorstein N H (1983) Rapid down-regulation of serotonin2 receptor binding during combined administration of tricyclic antidepressant drugs and α2 antagonists. Neuropharmacology22: 1203–1209
66.
Da-Rocha Jr M A, Puech A, Thiebot M H (1997) Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice. J Pharmacol11: 211–218
67.
Darracq L, Blanc G, Glowinski J, Tassin J P (1998) Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of d-amphetamine. J Neurosci18: 2729–2739
68.
Dassa D, Kaladjian A, Azorin J M, Giudicelli S (1993) Clopazine in the treatment of psychotic refractory depression. Br J Psychiatry163: 822–824
69.
Davidson C, Stamford J A (1995) Evidence that 5hydroxytryptamine release in rat dorsal raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1D autoreceptor. Br J Pharmacol114: 1107–1109
70.
Dawson L A, Nguyen H Q (1998) Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur J Pharmacol345: 41–46
71.
De Battista C, Sofuoglu M, Schatzberg A F (1998) Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs. Biol Psychiatry44: 336–340
72.
De Boer T, Nefkens F, Van Helvoirt A, Van Delft A M L (1996) Differences in modulation of noradrenergic and serotonergic transmission by the alpha2-adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther277: 852–860
73.
De Deurwaerdere P, Stinus L, Spampinato U (1998) Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors. J Neurosci18: 6528–6538
74.
De Deurwaerdère P, Spampinato U (1999) Role of serotonin2A and serotonin2B/2C receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J Neurochem73: 1033–1042
75.
Deakin J F W (1996) 5-HT, antidepressant drugs and the psychosocial origins of depression. J Psychopharmacol10: 31–38
76.
Diaz J, Lévesque D, Lammers C H, Griffon N, Martres M-P, Schwartz J-C, Sokoloff P (1995) Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience65: 731–745
77.
Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1998) Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology37: 265–272
78.
Dickinson S L (1991) Alpha2-adrenoceptor antagonism and depression. Drug News Perspect4: 197–203
79.
Dimitriou E C, Dimitriou C E (1998) Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol18: 465–469
80.
Done C J G, Sharp T (1992) Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo. Br J Pharmacol107: 240–245
81.
Done C J G, Sharp T (1994) Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology33: 411–421
82.
Dorsey C M, Lukas S E, Cunningham S L (1996) Fluoxetine-induced sleep disturbance in depressed patients. Neuropsychopharmacology14: 437–442
83.
Driver H S, Flanigan M J, Bentley A J, Luus H G, Shapiro C M, Mitchell D (1995) The influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects. Psychopharmacology117: 186–192
84.
Dubini A, Bosc M, Polin V (1997) Do noradrenaline and serotonin differentially affect social motivation and behaviour?Eur Neuropsychopharmacol7: S49–S55
85.
Duncan G E, Knapp D J, Little K Y, Breese G R (1994) Neuroanatomical specificity and dose dependence in the time course of imipramine-induced beta adrenergic receptor downregulation in rat brain. J Pharmacol Exp Ther271: 1699–1704
86.
Ekman A, Nissbrandt H, Heilig M, Dijkstra D, Eriksson E (1998) Central administration of dopamine D3 receptor antisense to rat: effects on locomotion, dopamine release and [3H]spiperone binding. Naunyn-Schmiedeberg's Arch Pharmacol358: 342–350
87.
Espejo E F (1997) Selective dopamine depletion within the medial prefrontal cortex induces anxiogenic-like effects in rats placed on the elevated plus maze. Brain Res762: 281–284
88.
Esposito E (1996) An indirect action for fluoxetine on the dopamine neurotransmitter system. Trends Pharmacol Sci17: 400–401
89.
Evins A E, Goff D C (1996) Adjunctive antidepressant drugs in schizophrenia. CNS Drugs6: 130–147
90.
Ferré S, Cortès R, Artigas F (1994) Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J Neurosci14: 4839–4846
91.
Finn M, Sukoff S I, Rosenzweig-Lipson S (1998) Modification of the behavioral effects of fluoxetine by WAY 100635 in rodents. Am Soc Neurosci Abstr24: 539.15–539.15
92.
Fletcher A, Forster E A, Bill D J, Brown G, Cliffe I A, Hartley J E, Jones D E, McLenachan A, Stanhope K J, Critchley D J P, Childs K J, Middlefell V C, Lanfumey L, Corradetti R, Laporte A M, Gozlan H, Hamon M, Dourish C T (1996) Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res73: 337–353
93.
Fletcher P J (1991) Dopamine receptor blockade in nucleus accumbens or caudate nucleus differentially affects feeding induced by 8-OH-DPAT injected into dorsal or median raphe. Brain Res552: 181–189
94.
Forbes I T, Jones G E, Murphy O E, Holland V, Baxter G S (1996) N-(1Methyl-5-indolyl)-N[.minute]-3-methyl-5-isothiazolyl)urea: a novel, highaffinity 5-HT2B receptor antagonist. J Med Chem38: 855–857
95.
Frazer A (1997) Antidepressants. J Clin Psychiatry58: 9–25
96.
Gainetdinov R R, Sotnikova T D, Grekhova T V, Rayevsky K S (1996) In vivo evidence for a preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol308: 261–269
97.
Galloway M P, Suchowski C S, Keegan M J, Hjorth S (1993) Local infusion of the selective 5-HT1B agonist CP93 129 facilitates striatal dopamine release in vivo. Synapse15: 90–92
98.
Gartside S E, Umbers V, Hajós M, Sharp T (1995) Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol115: 1064–1070
99.
Gaster L M, Blaney F E, Davies S, Duckworth M, Ham P, Jenkins A J, Joiner G F, King F D, Mulholland K R, Wyman P A, Hagan J J, Hatcher J, Jones B J, Middlemiss D N, Price G W, Riley G, Roberts C, Routledge C, Selkirk J, Slade P D (1998) The selective 5-HT1B receptor inverse agonists 1[.minute]-methyl-5-[[2[.minute]-methyl-4[.minute]-(5methyl-1, 2, 4-oxadiazol-3-yl) biphenyl-4-yl]-2, 3, 6, 7-tetrahydrospiro[furo[2, 3-f]indole-3–4[.minute]-piperidine]] (SB-224289) potently blocks terminal 5-HT autoreceptor-mediated control of release. Neuroscience84: 413–429
100.
Giardina W J, Buckner S A, Brune M E, Hancock A A, Wismer C T, Milicic I, Rattin J, Roux S, Wettstein J G, Meyer M D, Porsolt R D, Kerwin Jr J F, Williams M (1995) A-80426, a potent and selective [.alpha]2-adrenoceptor antagonist with serotonin uptakeblocking activity and putative antidepressant-like effects: II. Pharmacology profile. Drug Dev Res35: 246–260
101.
Giros B, Wang Y M, Suter S, McLeskey S B, Pifl C, Caron M G (1994) Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopaminenorepinephrine transporters. J Biol Chem269: 15985–15988
102.
Glassman A H (1998) Cardiovascular effects of antidepressant drugs: updated. Clin Psychiatry59: 13–18
103.
Gobbi M, Frittoli E, Mennini T (1993) Further studies on [.alpha]2-adrenoceptor subtypes involved in the modulation of [3H] noradrenaline and [3H]5-hydroxytryptamine release from rat brain cortex synaptosomes. J Pharmacol45: 811–814
104.
Gobert A, Millan M J (1999a) Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine (DA) and noradrenaline (NA), but not 5-HT, in the frontal cortex (FCX) of freely moving rats. Neuropharmacology38: 315–317
105.
Gobert A, Millan M J (1999b) Modulation of dialysate levels of dopamine, noradrenaline and serotonin (5-HT) in the frontal cortex of freely moving rats by (–)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of [.beta]-adrenergic, 5-HT1A and 5-HT1B receptors. Neuropsychopharmacology21: 268–284
106.
Gobert A, Lejeune F, Rivet J-M, Audinot V, Newman-Tancredi A, Millan M J (1995a) Modulation of the activity of central serotoninergic neurones by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurones in individual rats. J Pharmacol Exp Ther273: 1032–1046
107.
Gobert A, Rivet J-M, Audinot V, Cistarelli L, Spedding M, Vian, J, Peglion, J-L, Millan M J (1995b) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist (+)-S 14297. II: both D2 and ‘silent’ D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther275: 899–913
108.
Gobert A, Lejeune F, Rivet J-M, Cistarelli L, Millan M J (1996) Dopamine D3 (auto)receptors inhibits dopamine release in the frontal cortex of freely moving rats in vivo. J Neurochem66: 2209–2212
109.
Gobert A, Rivet J-M, Cistarelli L, Melon C, Millan M J (1997a) Alpha2-adrenergic receptor blockade markedly potentiates duloxetineand fluoxetine-induced increases in noradrenaline, dopamine and serotonin levels in the frontal cortex of freely moving rats. J Neurochem69: 2616–2619
110.
Gobert A, Rivet J-M, Cistarelli L, Millan M J (1997b) Buspirone enhances duloxetineand fluoxetine-induced increase in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem68: 1326–1329
111.
Gobert A, Rivet J-M, Cistarelli L, Millan M J (1997c) Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100 635 and GR 127 935. J Neurochem68: 1159–1163
112.
Gobert A, Rivet J-M, Audinot V, Newman-Tancredi A, Cistarelli L, Millan M J (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely moving rats reveals a complex pattern of reciprocal autoand heteroreceptor-mediated control of release. Neuroscience84: 413–429
113.
Gobert A, Lejeune F, Adhumeau A, Millan M J (1999a) Mirtazapine enhances dopaminergic and adrenergic, but not serotonergic, transmission in rats: an electrophysiological and dialysis comparison to fluoxetine. Am Soc Neurosci Abstr25: 533.11–533.11
114.
Gobert A, Rivet J-M, Cistarelli L, Melon C, Millan M J (1999b) Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of [.beta]2-adrenergic receptors underlies its actions. Neuroscience93: 1251–1262
115.
Gobert A, Dekeyne A, and Millan M J (in press a) The ability of WAY100, 635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224, 289, but not BRL15572. Neuropharmacology39-39
116.
Gobert A, Rivet J-M, Lejeune F, Newman-Tancredi A, Nicolas J-P, Cistarelli L, Melon C, Millan M J (in press b) Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse36-36
117.
Goff D C, Midha K K, Sarid-Segal O, Hubbard J W, Amico E (1995) A placebo-controlled trial of fluoxetine added to neuroleptics in patients with schizophrenia. Psychopharmacology117: 417–423
118.
Goldman-Rakic P S, Selemon L D (1997) Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull23: 437–458
119.
Goldstein B J, Goodnick P J (1998) Selective serotonin reuptake inhibitors in the treatment of affective disorders – III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol12: S55–S87
120.
Gonzalez L E, Ouagazzal A M, File S E (1998) Stimulation of benzodiazepine receptors in the dorsal hippocampus and median raphe reveals differential GABAergic control in two animal tests of anxiety. Eur J Neurosci10: 3673–3680
121.
Goodnick P J, Goldstein B J (1998a) Selective serotonin reuptake inhibitors in affective disorders – I. Basic pharmacology. J Psychopharmacol12: S5–S20
122.
Goodnick P J, Goldstein B J (1998b) Selective serotonin reuptake inhibitors in affective disorders – II. Efficacy and quality of life. J Psychopharmacol12: S21–S54
123.
Goodwin G M (1997) Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. J Psychopharmacol11: 115–122
124.
Gram L F, Fredricson-Overo K (1972) Drug interactions: inhibitory effects of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J1: 463–465
125.
Greenberg B D, Benjamin J, Martin J D, Keuler D, Huang S J, Altemus M, Murphy D L (1998) Delayed obsessive–compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Psychopharmacology140: 434–444
126.
Grenhoff J, Nisell M, Ferré S, Aston-Jones G, Svensson T H (1993) Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm93: 11–25
127.
Gresch P, Sved A F, Zigmond M J, Finlay J M (1995) Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem65: 111–116
128.
Griebel G, Perrault G, Sanger D J (1997) A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology36: 793–802
129.
Griffon N, Pilon C, Sautel F, Schwartz J-C, Sokoloff P (1996) Antipsychotics with inverse agonist activity at the dopamine D3 receptor. J Neural Transm103: 1163–1175
130.
Grignaschi G, Invernizzi R W, Fanelli E, Fracasso C, Caccia S, Samanin R (1998) Citalopram-induced hypophagia is enhanced by blockade of 5-HT1A receptors: role of 5-HT2C receptors. Br J Pharmacol124: 1781–1787
131.
Gu H, Wall S C, Rudnick G (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics and ion dependence. J Biol Chem269: 7124–7130
132.
Gurevich E V, Joyce J N (1999) Distribution of dopamine D3 receptor-expressing neurons in the human forebrain. Neuropsychopharmacology20: 61–80
133.
Haddjeri N, Blier P, De Montigny C (1996) Effects of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther277: 861–871
134.
Haddjeri N, Blier P, De Montigny C (1998) Long-term antidepressant treatment results in a tonic activation of forebrain 5-HT1A receptors. J Neurosci18: 10150–10156
135.
Hall D A, Strange P G (1997) Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors. Br J Pharmacol121: 731–736
136.
He H, Richardson J S (1997) Nefazodone: a review of its neurochemical mechanisms, pharmacokinetics and therapeutic use in major depressive disorder. CNS Drug Reviews3: 34–48
137.
Heisler L K, Baïwa P, Tecott L H (1998a) Altered anxiety-like behavior in 5-HT2C receptor null mutant mice. Am Soc Neurosci Abstr24: 238.10–238.10
138.
Heisler L K, Chu H M, Brennan T J, Danao J A, Bajwa P, Parsons L H, Tecott L H (1998b) Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci USA95: 15049–15054
139.
Herrero I, Sánchez-Prieto J (1996) cAMP-dependent facilitation of glutamate release by [.beta]-adrenergic receptors in cerebrocortical nerve terminals. J Biol Chem271: 30554–30560
140.
Herroelen L, De Backer J P, Wilczak N, Flamez A, Vauqelin G, De Keyser J (1994) Autoradiographic distribution of D3-type dopamine receptors in human brain using 7-[3H]hydroxy-N, N-di-n-propyl-2-aminotetralin. Brain Res648: 222–228
141.
Hertel P, Lindblom N, Nomikos G G, Svensson T H (1998) Modulation of central serotonergic transmission by risperidone: underlying mechanism(s) significance of action. Prog NeuroPsychopharmacol Biol Psychiatr22: 815–834
142.
Hervàs I, Artigas F (1998) Effect of fluoxetine on cellular 5hydroxytryptamine in rat brain. Role of 5-HT autoreceptors. Eur J Pharmacol358: 9–18
143.
Hieble J P, Ruffolo Jr R R (1996) Subclassification and nomenclature of [.alpha]1 and [.alpha]2-adrenoceptors. Prog Drug Res47: 1906–1912
144.
Hieble J P, Ruffolo Jr R R (1997) Recent advances in the identification of [.alpha]1 and [.alpha]2-adrenoceptor subtypes: therapeutic implications. Exp Opin Invest Drugs6: 367–387
145.
Hjorth S (1998) In vivorat brain microdialysis studies of the novel, selective 5-HT1B receptor antagonist NAS-181. Am Soc Neurosci Abstr24: 438.13–438.13
146.
Hjorth S, Sharp T (1991) Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median rapheinnervated rat brain regions as measured by in vivo microdialysis. Life Sci48: 1779–1786
147.
Hjorth S, Sharp T (1993) In vivo microdialysis evidence of central serotonin1A and serotonin1B autoreceptor blocking properties of the beta adrenoceptor antagonist (–)-penbutolol. J Pharmacol Exp Ther265: 707–712
148.
Hjorth S, Bengtsson H J, Milano S, Lundberg J F, Sharp T (1995) Studies on the role of 5-HT1A autoreceptors and [.alpha]1-adrenoceptors in the inhibition of 5-HT release. I. BMY7378 & prazosin. Neuropharmacology34: 383–392
149.
Hjorth S, Carlsson A, Lindberg P, Sanchez D, Wikstrom D, Arvidsson L-E, Hacksell U, Nilsson J L G (1982) 8-hydroxy-2-(din-propylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT stimulating activity. J Neural Transm55: 169–179
150.
Hogarty G E, McEvoy J P, Ulrich R F, DiBarry A L, Bartone P, Cooley S, Hammill K, Carter M, Munetz M R, Perel J (1995) Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry52: 29–41
151.
Hughes Z A, Stanford S C (1996) Increased noradrenaline efflux induced by local infusion of fluoxetine in the rat frontal cortex. Eur J Pharmacol317: 83–90
152.
Hughes Z A, Stanford S C (1998) Evidence from microdialysis and synaptosomal studies of rat cortex for noradrenaline uptake sites with different sensitivities to SSRIs. Br J Pharmacol124: 1141–1148
153.
Hunter J C, Fontana D J, Hedley L R, Jasper J R, Lewis R, Link R, Secchi R, Sutton J, Eglen R M (1997) Assessment of the role of alpha2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol122: 1339–1344
154.
Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol9: 19–26
155.
Ichikawa J, Meltzer H Y (1995) Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol281: 255–261
156.
Ichikawa J, Kuroki T, Dai J, Meltzer H Y (1998) Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol351: 163–171
157.
Invernizzi R, Velasco C, Bramante M, Longo A, Samanin R (1997) Effects of 5-HT1A receptor antagonists on citalopram-induced increases in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus. Neuropharmacology36: 467–473
158.
Iyer R N, Bradberry C W (1996) Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther277: 40–47
159.
Jackson D M, Westlind-Danielsson A (1994) Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Ther64: 291–369
160.
Jenck F, Moreau J-L, Martin J R, Haefely W E (1993) Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol231: 223–226
161.
Jenck F, Moreau J-L, Mutel V, Martin J R (1994) Brain 5-HT1C receptors and antidepressants. Prog NeuroPsychopharmacol Biol Psychiatry18: 563–574
162.
Jenck F, Moreau J-L, Berendsen H H, Boes M, Broekkamp C L E, Martin J R, Wichmann J, Van Delft A M L (1998) Antiaversive effects of 5-HT2C receptor agonists and fluoxetine in a model of panic–like anxiety in rats. Eur Neuropsychopharmacol8: 161–168
163.
Johnson S W, Mercuri N B, North R A (1992) 5-hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurones. J Neurosci12: 2000–2006
164.
Jonas J M, Cohon M S (1993) A comparison of the safety and efficacy of alprazolam versus other agonists in the treatment of anxiety, panic and depression: a review of the literature. J Clin Psychiatry54: 25–45
165.
Jordan S, Kramer G L, Zukas P K, Moeller M, Petty F (1994) In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine and fluvoxamine. Synapse18: 294–297
166.
Katz R J, Rosenthal M (1994) Adverse interaction of cyproheptadine with serotonergic antidepressants. J Clin Psychiatry55: 314–315
167.
Kelland M D, Chiodo L A (1996) Serotoninergic modulation of midbrain dopamine systems. In Ashby C R Jr (eds), The modulation of dopaminergic neurotransmission by other neurotransmitters. CRC Press, New York, pp. 87–122
168.
Kelly M A, Rubinstein M, Phillips T J, Lessov C N, Burkhart-Kasch S, Zhang G, Bunzow J R, Fang Y, Gerhart G A, Grandy D K, Low M J (1998) Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background and developmental adaptations. J Neurosci18: 3470–3479
169.
Kennett G A, Wood M D, Bright F, Cilia J, Piper D C, Gager T, Thomas D, Baxter G S, Forbes I T, Ham P, Blackburn T P (1996) In vitroand in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol117: 427–434
170.
Kennett G A, Ainsworth K, Trail B, Blackburn TP (1997a) BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology36: 233–239
171.
Kennett G A, Wood M D, Bright F, Trail B, Riley G, Holland V, Avenell K Y, Stean T, Upton N, Bromidge S, Forbes I T, Brown A M, Midlemiss D N, Blackburn T P (1997b) SB242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology36: 609–620
172.
Kent J M, Coplan J D, Gorman J M (1998) Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry44: 812–824
173.
Kessler R M, Rieck R W, Mason N S, Ansari M S, Whetsell W O Jr (1998) [125I]Norepidepride, a D3 preferring ligand, characterization and autoradiographic localization. Am Soc Neurosci Abstr24: 340.3
174.
Khan Z U, Gutierrez A, Martin R, Penafiel A, Rivera A, De La Calle A (1998) Differential regional and cellular distribution of dopamine D2-like receptors: an immunocytochemical study of subtype-specific antibodies in rat and human brain. J Comp Neurol402: 353–371
175.
Kibel D A, Laffont I, Liddle P F (1993) The composition of the negative syndrome of chronic schizophrenia. Br J Psychiatry162: 744–750
176.
King J A, Edwards E, Ferris C F, Springer C, Lahti K (1998) Imaging depression in fully conscious learned helpless rats using functional MRI. Am Soc Neurosci Abstr24: 484.18–484.18
177.
Kiss J P, Zsilla G, Mike A, Zelles T, Toth E, Lajtha A, Vizi E S (1995) Subtype-specificity of the presynaptic [.alpha]2-adrenoceptors modulating hippocampal norepinephrine release in rat. Brain Res674: 238–244
178.
Klysner R, Geisler A (1991) Rapid downregulation of cerebral [.beta]-adrenoceptors by combined treatment with imipramine and mianserin. In Jay D (ed), Advances in neuropsychiatry and psychopharmacology: refractory depression. Raven Press Ltd. Amsterdam 2: 109–113
179.
Koeltzow T E, Xu M, Cooper D C, Hu X T, Tonegawa S, Wolf M E, White F J (1998) Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J Neurosci18: 2231–2238
180.
Kotrla K J, Weinberger D R (1995) Brain imaging in schizophrenia. Annu Rev Med46: 113–122
181.
Kreiss D S, Bergstrom D A, Gonzalez A M, Huang K X, Sibley D R, Walters J R (1995) Dopamine receptor agonists potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol277: 209–214
182.
Kuikka J T, Pitkanen A, Lepola U, Partanen K, Vainio P, Bergstrom K A, Wieler H J, Kaiser K P, Mittelbach L, Koponen H, Leinonen E, Riekkinen PJ (1995) Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex of patients with panic disorder. Nucl Med Commun16: 273–280
183.
Kuroki T, Meltzer H Y, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther288: 774–781
184.
Lakhlani P P, MacMillan L B, Guo T Z, McCool B A, Lovinger D M, Maze M, Limbrid L E (1997) Substitution of a mutant alpha2A-adrenergic receptor via ‘hit and run’ gene targeting reveals the role of this subtype in sedative, analgesic and anestheticsparing responses in vivo. Proc Natl Acad Sci USA94: 9950–9955
185.
Lauritzen L, Clemmesen L, Klysner R, Loldrup D, Lunde M, Schaumburg E, Waarst S, Bech P (1992) Combined treatment with imipramine and mianserin. Pharmacopsychiatry25: 182–186
186.
Le Moal M, Simon H (1991) Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev71: 155–234
187.
Lee A, Rosin D L, Van Bockstaele E J (1998a) [.alpha]2A-adrenergic receptors in the rat nucleus locus coeruleus: subcellular localization in catecholaminergic dentrites, astrocytes and presynaptic axon terminals. Brain Res795: 157–169
188.
Lee A, Wissekerke A E, Rosin D L, Lynch K R (1998b) Localization of [.alpha]2C-adrenergic receptor immunoreactivity in catecholaminergic neurons in the rat central nervous system. Neuroscience84: 1085–1096
189.
Lejeune F, Millan M J (1995) Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurons in vivo. Eur J Pharmacol275: R7–R9
190.
Lejeune F, Millan M J (1998) Induction of burst firing in ventral tegmental area dopaminergic neurones by activation of serotonin (5-HT)1A receptors: WAY 100, 635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse30: 1–9
191.
Lejeune F, Audinot V, Gobert A, Rivet J-M, Spedding M, Millan M J (1994) Clozapine inhibits serotoninergic transmission by an action at [.alpha]1-adrenoceptors not at 5-HT1A receptors. Eur J Pharmacol260: 79–83
192.
Lejeune F, Gobert A, Rivet J-M, Millan M J (1997a) Serotonin (5HT)2C receptors modulate the activity of mesocortical and mesolimbic dopaminergic pathways: a combined dialysis and electrophysiological analysis. Am Soc Neurosci Abstr23: 386.13
193.
Lejeune F, Newman-Tancredi A, Audinot V, Millan M J (1997b) Interactions of (+)and (–)-8and 7-OH-DPAT at human (h)D3, hD2 and 5-HT1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. J Pharmacol Exp Ther280: 1241–1249
194.
Lejeune F, Gobert A, Rivet J-M, Melon C, Cistarelli L and Millan M J (1998) (–)-Pindolol increases dialysate levels of dopamine (DA) and noradrenaline (NAD), but not serotonin (5-HT), in the frontal cortex (FCX) of freely moving rats. Am Soc Neurosci Abstr24: 341.11
195.
Leonard B E (1997) The role of noradrenaline in depression: a review. J Psychopharmacol11: S39-S47
196.
Levant B (1998) Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res800: 269–274
197.
L'hirondel M, Cheramy A, Godeheu G, Artaud F, Saiardi A, Borelli E, Glowinski J (1998) Lack of autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes of D2 receptor-deficient mice. Brain Res792: 253–262
198.
Lloyd K G, Zivkovic B, Scatton B, Morselli P L, Bartholini G (1989) The GABAergic hypothesis of depression. Prog NeuroPsychopharmacol Biol Psychiatry13: 341–351
199.
Lucki I, Singh A, Kreiss D S (1994) Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci Biobehav Rev18: 85–95
200.
Luscombe G P, Martin K F, Hutchins L J, Gosden J, Heal D J (1993) Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors. Br J Pharmacol108: 669–677
201.
Maes M, Meltzer H Y (1995) The serotonin hypothesis of major depression. In Bloom F E, Kupfer D J (eds), Psychopharmacology: the fourth generation in progress. Raven Press Ltd, New York, pp. 933–944
202.
Malison R T, Price L H, Berman R, Van Dyck C H, Pelton G H, Carpenter L, Sanacora G, Owens M J, Nemeroff C B, Rajeevan N, Baldwin R M, Seibyl J P, Innis R B, Charney D S (1998) Reduced brain serotonin transporter availability in major depression as measured by [123I]-2[.beta]-carbomethoxy-3[.beta]-(4iodophenyl) tropane and single photon emission computed tomography. Biol Psychiatry44: 1090–1098
203.
Malmberg A, Mikaels A, Mohell N (1998) Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5[.minute]-[[.gamma]-thio]triphosphate-[35S] binding. J Pharmacol Exp Ther285: 119–126
204.
Martin J R, Bös M, Jenck F, Moreau J-L, Mutel V, Sleight A J, Wichmann J, Andrews J S, Berendsen H H G, Broekkamp C L E, Ruigt G S F, Köhler C, Van Delft A M L (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther286: 913–924
205.
Mateo Y, Pineda J, Meana J J (1998) Somatodendritic [.alpha]2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant, desipramine. J Neurochem71: 790–798
206.
Matos F F, Urban C, Eison A S, Yocca F (1994) Effects of chronic treatment with BMS-18101 and fluoxetine on extracellular serotonin (5-HT) in guinea pig frontal cortex. In Louilot A, Durkin T, Spampinato U, Cador M (eds), Monitoring molecules in neuroscience, Proceedings of the 6th International Conference on in vivoMethods, pp. 207–208
207.
Maura G, Bonanno G, Raiteri M (1992) Presynaptic [.alpha]2-adrenoceptors mediating inhibition of noradrenaline and 5hydroxytryptamine release in rat cerebral cortex: further characterization as different [.alpha]2-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch Pharm345: 410–416
208.
Maurel-Rémy S, Bervoets K, Millan M J (1995) Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100 907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol280: R9–R11
209.
Mayberg H S, Brannan S K, Mahurin R K, Jerabek P A, Brickman J S, Tekell J L, Silva J A, McGinnis S, Glass T G, Martin C C, Fox P T (1997) Cingulate function in depression: a potential predictor of treatment response. NeuroReport8: 1057–1061
210.
McAskill R, Mir S, Taylor D (1998) Pindolol augmentation of antidepressant therapy. Br J Pharmacol173: 203–208
211.
McDougle C J, Goodman W K, Leckman J C, Lee N C, Heninger G R, Price L H (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebocontrolled study in patients with and without tics. Arch Gen Psychiatry51: 302–308
212.
McPhillips M A, Barnes T R E (1997) Negative symptoms. Curr Opin Psychiatry10: 30–35
213.
Meador-Woodruff J H, Damask S P, Watson S J (1994) Differential expression of autoreceptors in the ascending dopamine system of the human brain. Proc Natl Acad Sci USA91: 8297–8301
214.
Meller E, Goldstein M, Bohmaker K (1990) Receptor reserve for 5hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5hydroxytryptamine1A agonists. Mol Pharmacol37: 231–237
215.
Meltzer H Y (1995) Atypical antipsychotic drugs. In Bloom F E, Kupfer D J (eds), Psychopharmacology: the fourth generation in progress. Raven Press Ltd, New York, pp. 1277–1286
216.
Meltzer H Y, Maes M (1994) Effect of pindolol on the L-5-HTPinduced increase in plasma prolactin and cortisol concentrations in man. Psychopharmacology114: 635–643
217.
Menkes D B (1995) Buspirone augmentation of sertraline. Br J Psychiatry166: 823–824
218.
Mendlin A, Martin F J, Jacobs B L (1999) Dopaminergic input is required for increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in rat forebrain. Neuroscience93: 897–905
219.
Mercuri N B, Saiardi A, Bonci A, Picetti R, Calabresi P, Bernardi G, Borreli E (1997) Loss of autoreceptor function in dopaminergic neurones from dopamine D2 receptor deficient mice. Neuroscience79: 323–327
220.
Meyer M D, Hancock A A, Tietje K, Sippy K B, Prasad R, Stout D M, Arendsen D L, Donner B G, Caroll W A (1997) Structure-activity studies for a novel series of N(Arylethyl)-N-(1, 2, 34, tetrahydronaphtalen-1-ylmethyl)-N-methylamines possessing dual 5-HT uptake inhibiting and [.alpha]2-antagonistic activities. J Med Chem40: 1049–1062
221.
Miczek K A, Weerts E, Vivian J A, Barros H M (1995) Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics. Psychopharmacology121: 38–56
222.
Mielke R, Kessler J, Szelies B, Herhorlz K, Wienhard K, Heiss W D (1998) Normal and pathological ageing-findings of positronemission-tomography. J Neural Transm105: 821–837
223.
Millan M J, Gobert A (1999) (–)-Pindolol increases dialysate concentrations of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. Neuropharmacology38: 909–912
224.
Millan M J, Perrin-Monneyron S (1997) Potentiation of fluoxetineinduced penile erections by combined blockade of 5-HT1A and 5-HT1B receptors. Eur J Pharmacol321: R11–R13
225.
Millan M J, Rivet J-M, Canton H, Lejeune F, Bervoets K, Brocco M, Gobert A, Lefèbvre De Ladonchamps B, Le Marouille-Girardon S, Verrièle L, Laubie M, Lavielle G (1992) S 14671: a naphtylpiperazine 5-hydroxytryptamine1A agonist of exceptional potency and high efficacy possessing antagonist activity at 5-HT1C/2 receptors. J Pharmacol Exp Ther262: 451–463
226.
Millan M J, Bervoets K, Rivet J-M, Widdowson P, Renouard A, Le Marouille-Girardon S, Gobert A (1994) Multiple alpha2-adrenergic receptor subtypes. II. Evidence for a role of rat r[.alpha]2A-ARs in the control of nociception, motor behaviour and hippocampal synthesis of noradrenaline. J Pharmacol Exp Ther270: 958–972
227.
Millan M J, Hjorth S, Samanin R, Schreiber R, Jaffard R, De Ladonchamps B, Veiga S, Goument B, Peglion J-L, Spedding M, Brocco M (1997a) S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. J Pharmacol Exp Ther282: 148–161
228.
Millan M J, Newman-Tancredi A, Rivet J-M, Brocco M, Lacroix P, Audinot V, Cistarelli L, Gobert A (1997b) S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h[.alpha]2A-adrenergic receptors in relation to modulation of cortical monoamine release and potential antidepressant properties. J Pharmacol Exp Ther282: 132–147
229.
Millan M J, Brocco M, Veiga S, Cistarelli L, Melon C, Gobert A (1998a) WAY 100, 635 enhances both the ‘antidepressant’ actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex. Eur J Pharmacol341: 165–167
230.
Millan M J, Dekeyne A, Gobert A (1998b) Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NAD), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology37: 953–955
231.
Millan M J, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet J-M, Cussac D, Nicolas J P, Muller O, Lavielle G (1998c) S 16924 ((+)-2-{1-[2-(2, 3-dihydro-benzo[1, 4] dioxin-5-yloxy)-ethyl]pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties. I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther286: 1341–1355
232.
Millan M J, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet J-M, Schreiber R, Dekeyne A, Spedding M, Nicolas J-P, Peglion J-L (1998d) S 18126 ({2-[4-(2, 3-dihydrobenzo [1, 4]dioxin-6-yl) piperazin-1-yl methyl] indan-2-yl}): a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison to L 745 870 (3-(4-[4chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride. J Pharmacol Exp Ther287: 167–186
233.
Millan M J, Brocco M, Dekeyne A, Newman-Tancredi A, Cussac D, Lejeune F, Rivet J-M, Gobert A, Audinot V, Sezgin L, Despaux N, Peglion J-L (1999a) S 32504, a novel and potent naphtoxazine agonist at dopamine D3 receptors. Am Soc Neurosci Abstr25: 588.2-588.2
234.
Millan M J, Brocco M, Gobert A, Schreiber R, Dekeyne A (1999b) S 16924 ((R)-2-{1-[2-(2, 3-dihydro-benzo[1, 4] dioxin-5-yloxy)-ethyl]pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol. J Pharmacol Exp Ther288: 1002–1014
235.
Millan M J, Gobert A, Audinot V, Dekeyne A, Newman-Tancredi A (1999c) Inverse agonists and serotonergic transmission: from recombinant human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures. Neuropsychopharmacology21: 61S–67S
236.
Millan M J, Gobert A, Girardon S, Dekeyne A (1999d) Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin as compared to dopamine and noradrenaline. Eur J Pharmacol364: 147–150
237.
Millan M J, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas J P, Cogé F, Galizzi J P, Boutin J A, Rivet J-M, Dekeyne A, Gobert A (2000) Agonist and antagonist actions of yohimbine as compared to fluparoxan at [.alpha]2-adrenergic receptors (AR)s, serotonin (5-HT)1A, 5-HT1B, 5-HT1D, and dopamine D2 and D3 receptors: significance for the modulation of frontocortical monoaminergic transmission and depressive state. Synapse35: 72–95
238.
Millan M J, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet, J-M, Audinot V, Dubuffet T, Lavielle G (in press a) S33084, a novel, potent, selective and competitive antagonist at dopamine D3-receptors: I. Receptorial, electrophysiological and neurochemical profile in comparison to GR218, 231 and L741, 626. J Pharmacol Exp Ther
239.
Millan M J, Gobert A, Rivet J-M, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas J-P, Lejeune F (in press b) Mirtazapine enhances frontocortical dopminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of [.alpha]2-adrenergic and serotonin2C receptors: a comparison to citalopram. Eur J Neurosci12-12
240.
Mir S, Taylor D (1997) The adverse effects of antidepressants. Curr Opin Psychiatry10: 88–94
241.
Misu Y, Kubo T (1986) Presynaptic [.beta]-adrenoceptors. Med Res Rev6: 197–225
242.
Mongeau R, De Montigny C, Blier P (1993) In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of [.alpha]2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedeberg's Arch Pharmacol347: 266–272
243.
Mongeau R, de Montigny C, Blier P (1994a) Effects of long-term alpha-2 adrenergic antagonist and electroconvulsive treatment on alpha-2 adrenoceptors modulating serotonin neurotransmission. J Pharmacol Exp Ther269: 1152–1159
244.
Mongeau R, de Montigny C, Blier P (1994b) Effects of long-term administration of antidepressant drugs on the 5-HT3 receptors that enhance the electrically evoked release of [3H]noradrenaline in the rat hippocampus. Eur J Pharmacol271: 121–129
245.
Morgan M, LeDoux E (1995) Differential contribution of dorsal and ventral medial prefrontal cortex to the acquisition and extinction of conditioned fear in rats. Behav Neurosci109: 681–688
246.
Morilak D A, Garlow S J, Ciaranello R D (1993) Immunocytochemical localization and description of neurons expressing serotonin2 receptors in the rat brain. Neuroscience54: 701–717
247.
Mos J, Mollet I, Tolboom J T B M, Waldinger M D, Olivier B (1999) A comparison of the effects of different serotonin reuptake blockers on sexual behaviour of the male rat. Eur Neuropsychopharmacol9: 123–135
248.
Moser P C, Sanger D J (1996) Antagonism by WAY 100635, a 5-HT1A antagonist, of the effects of fluoxetine and befloxatone in the forced swim test. Am Soc Neurosci Abstr22: 76.11
249.
Mundo E, Guglielmo, Bellodi L (1998) Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol13: 219–224
250.
Murphy D L, Andrews A M, Wichems C H, Li Q, Tohda M, Greenberg B (1998) Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitters systems and consequent implications for the understanding the actions of serotonergic drugs. J Clin Psychiatry59: 4–12
251.
Murugaiah K D, O'Donnell J M (1995) Facilitation of noradrenaline release from rat brain slices by [.beta]-adrenoceptors. NaunynSchmiedeberg's Arch Pharmacol351: 483–490
252.
Nelson J C (1987) The use of antipsychotic drugs in the treatment of depression. Treat Resist Depress7: 131–146
253.
Nemeroff C B (1997) Augmentation strategies in patients with refractory depression. Depress Anxiety4: 169–181
254.
Newcomer J W, Faustman W O, Yeh W, Csernansky J G (1990) Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. Psychiatry Res31: 243–250
255.
Newman-Tancredi A, Verrièle L, Chaput C, Millan M J (1996) Downregulation of rat [.beta]-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [3H]CGP-12177 binding reveals rapid (24 hour) modulation. Brain Res Bull41: 93–96
256.
Newman-Tancredi A, Chaput C, Gavaudan S, Verrièle L, Millan M J (1998) Agonist and antagonist actions of (–)pindolol at recombinant, human 5-HT1A receptors. Neuropsychopharmacology18: 395–398
257.
Newman-Tancredi A, Cussac D, Audinot V, Pasteau V, Gavaudan S, Millan M J (1999) G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: a guanosine-5[.minute]-O-(3-[35S]thio)-triphosphate binding and antibody study. Mol Pharmacol55: 564–574
258.
Newton R A, Elliott J M (1997) Mianserin-induced down-regulation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors stably expressed in the human neuroblastoma cell line SH-SY5Y. J Neurochem69: 1031–1038
259.
Nicholas A P, Pieribone V A, Hökfelt T (1993) Cellular localization of messenger RNA for beta-1 and beta2 adrenergic receptors in rat brain: an in situ hybridization study. Neuroscience56: 1023–1039
260.
Nissbrandt H, Ekman A, Eriksson E, Heiling M (1995) Dopamine D3 receptor antisense influences dopamine synthesis in rat brain. NeuroReport6: 573–576
261.
Nolde S F, Johnson M K, D'Esposito M (1998) Left prefrontal activation during episodic remembering: an event-related fMRI study. NeuroReport9: 3509–3514
262.
O'Donnell J (1993) Effect of the beta-2 adrenergic agonist zinterol on noradrenaline turnover. Res Commun Chem Pathol Pharmacol80: 113–116
263.
O'Neil M F, Fernandez A G, Palacios J M (1996) GR 127935 blocks the locomotor and antidepressant-like effects of RU 24969 and the action of antidepressants in the mouse tail suspension test. Pharmacol Biochem Behav53: 535–539
264.
Ohmori T, Koyama T, Yamashita I (1990) Measurement of endogenous dopamine and norepinephrine release from superfused slices of rat prefrontal cortex in vitro: modulation by D2 and alpha2-presynaptic receptors. Life Sci48: 283–289
265.
Okada F, Tokumitsu Y (1994) Is the [.beta]-down-regulation a prerequisite of the antidepressant activity?J Psychopharmacol8: 62–63
266.
Olivier B, Van Oorschort R, Waldinger M D (1998) Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol13: S9–S14
267.
Osman O T, Potter W Z, Rudorfer M V (1989) Idazoxan: a selective alpha-2 antagonist and effective sustained antidepressant in two bipolar depressed patients. Arch Gen Psychiatry46: 958–959
268.
Pacholczyk T, Blakely R D, Amara S G (1991) Expression cloning of a cocaineand antidepressant-sensitive human noradrenaline transporter. Nature350: 350–354
269.
Palfreyman M G, Schmidt C J, Sorensen S M, Dudley M W, Kehne J H, Mose P, Gittos M W, Carr A A (1993) Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology112: S60–S67
270.
Palij P, Stamford J A (1996) Rauwolscine potentiates the effect of desipramine on limbic noradrenaline efflux. NeuroReport7: 1121–1124
271.
Palvimaki E P, Roth B L, Majusuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J (1996) Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor. Psychopharmacology126: 234–240
272.
Pan Z Z, Williams J T (1989) GABA and glutamate-mediated synaptic potentials in rat dorsal raphe neurons in vitro. J Neurophysiol61: 719–726
273.
Pazos A, Palacios J M (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. Serotonin-1 receptors. Brain Res346: 205–230
274.
Pehek E A, Crish S D (1998) The effects of selective serotonin 5HT2A and 5-HT2B/C ligands on in vivo dopamine release in the rat prefrontal cortex. Am Soc Neurosci Abstr24: 48.3
275.
Pennington N J (1996) Actions of methoxylated amphetamine hallucinogens on serotonergic neurons of the brain. Prog NeuroPsychopharmacol Biol Psychiatry20: 951–965
276.
Pessia M, Jiang Z G, North R A, Johnson S W (1994) Actions of 5hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res654: 324–330
277.
Petty F, Trivedi M H, Fulton M, Rush A J (1995) Benzodiazepines as antidepressants: does GABA play a role in depression?Biol Psychiatry38: 578–591
278.
Pinder R M, Wieringa J H (1993) Third-generation antidepressants. Med Res Rev13: 259–325
279.
Pineyro G, de Montigny C, Blier P (1995) 5-HT1D receptors regulate 5-HT release in the rat raphe nuclei. In vivovoltammetry and in vitrosuperfusion studies. Neuropsychopharmacology13: 249–260
280.
Pineyro G, de Montigny C, Weiss M, Blier P (1996) Autoregulatory properties of dorsal raphe 5-HT neurons. Possible role of electronic coupling and 5-HT1D receptors in the rat brain. Synapse22: 54–62
281.
Pollack M H, Hammerness P (1993) Adjunctive yohimbine for treatment in refractory depression. Biol Psychiatry33: 220–221
282.
Pompeiano M, Palacios J M, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Mol Brain Res23: 163–178
283.
Pozzi L, Invernizzi R, Cervo L, Vallebuona F, Samanin R (1994) Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem63: 195–200
284.
Price G W, Burton M J, Collin L J, Duckworth M, Gaster L, Göthert M, Jones B J, Roberts C, Waston J M, Middlemiss D N (1997) SB216241 and BRL-15572: compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. NaunynSchmiedeberg's Arch Pharmacol356: 312–330
285.
Prisco S, Esposito E (1995) Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br J Pharmacol116: 1923–1931
286.
Prisco S, Pagannone S, Esposito E (1994) Serotonin–dopamine interaction in the ventral tegmental area: an electrophysiological study in vivo. J Pharmacol Exp Ther271: 83–90
287.
Quested D J, Sargent P A, Cowen P J (1997) 5-HT2C receptor function is decreased by SSRI treatment. J Psychopharmacol11: A37-A37
288.
Ramboz S, Oosting R, Amara D A, Hung H F, Blier P, Mendelsohn M, Mann J J, Brunner D, Hen R (1998) Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci USA95: 14476–14481
289.
Redrobe J P, Bourin M (1997) Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol325: 129–135
290.
Redrobe J P, Bourin M (1998) Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psychopharmacology138: 198–206
291.
Redrobe J P, MacSweeney C P, Bourin M (1996) The role of 5-HT1A and 5-HT1B receptors with antidepressant drugs in the mouse forced swimming test. Eur J Pharmacol318: 213–220
292.
Reith M E A, Coffey L L, Xu C, Chen N H (1994) GBR 12909 and 12935 block dopamine uptake into brain synaptic vesicles as well as nerve endings. Eur J Pharmacol253: 175–178
293.
Reneric J P, Lucki I (1998) Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology136: 190–197
294.
Renouard A, Widdowson P S, Millan M J (1994) Multiple alpha2-adrenergic receptor subtypes. I. Comparison of [3H]RX821002labelled rat r[.alpha]2A-adrenergic receptors in cerebral cortex to human h[.alpha]2A-adrenergic receptors an other populations of [.alpha]2-adrenergic subtypes. J Pharmacol Exp Ther270: 946–957
295.
Richtand N M, Kelsoe J R, Segal D S, Kuczenski R (1995) Regional quantification of D1, D2 and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay. Mol Brain Res33: 97–103
296.
Rick C E, Stanford I M, Lacey M G (1995) Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5hydroxytryptamine2C receptors. Neuroscience69: 903–913
297.
Rickels K, Schweizer E, Clary C, Fox I, Weise C (1994) Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry164: 802–805
298.
Riva M, Brunello N, Rovescalli A C, Galimberti R, Carfagna N, Carminati P, Pozzi O, Ricciardi S, Roncucci R, Rossi A, Racagni G (1989) Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J Drug Dev1: 243–253
299.
Rivet J-M, Audinot V, Gobert A, Peglion J-L, Millan M J (1994) Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist (+)-S 14297. Eur J Pharmacol265: 175–177
300.
Rivet J-M, Gobert A, Cistarelli L, Girardon S, Millan M J (1996) The selective 5-HT2A receptor antagonist, MDL 100, 907, enhances PCP-induced dopamine release in the striatum of freely moving rats. In González-Mora J L, Borges R, Mas M (eds), Monitoring molecules in neuroscience, Proceedings of the 7th International Conference on in vivoMethods, pp. 103–104
301.
Rivet J-M, Gobert A, Cistarelli L, Melon C, Millan M J (1998) Antidepressants (ADs) differentially modify dialysate serotonin (5-HT), dopamine (DA) and noradrenaline (NAD) levels in rats. Am Soc Neurosci Abstr24: 440.9-440.9
302.
Roberts C, Price G W, Gaster L, Jones B J, Middlemiss D N, Routledge C (1997) Importance of 5-HT1B receptor selectivity for 5-HT terminal autoreceptor activity: an in vivo microdialysis study in the freely moving guinea-pig. Neuropharmacology36: 549–557
303.
Rogers M A, Bradshaw J L, Pantelis C, Phillips J G (1998) Frontostriatal deficits in unipolar major depression. Brain Res Bull47: 297–310
304.
Rollema H, Clarke T, Sprouse J S, Schultz D W (1996) Combined administration of a 5-hydroxytryptamine (5HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J Neurochem67: 2204–2207
305.
Rollema H, Lu Y, Schmidt A W, Zorn S H (1997) Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol338: R3–R5
306.
Rosen R C, Lane R M, Menza M (1999) Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol19: 67–85
307.
Rosin D L, Talley E M, Lee A, Stornetta R L, Gaylinn B D, Lynch K R (1996) Distribution of α2C-adrenergic receptor-like immunoreactivity in the rat central nervous system. J Comp Neurol372: 135–165
308.
Rossetti Z L, Portas C, Gessa G (1989) Brain dialysis provides evidence for D2-dopamine receptors modulating noradrenaline release in the rat frontal cortex. Eur J Pharmacol163: 393–395
309.
Rothschild A J, Samson J A, Bessette M P, Carter-Campbell J T (1993) Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry54: 338–342
310.
Rouquier L, Claustre Y, Benavides J (1994) [.alpha]1-Adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol261: 59–64
311.
Ruzicka B B, Jhamandas K H (1993) Excitatory amino acid action on the release of brain neurotransmitters and neuromodulators: biochemical studies. Prog Neurobiol40: 223–247
312.
Sachs G S, Pollack M H, Brotman A W, Farhadi A M, Gelenberg J (1986) Enhancement of ECT benefit by yohimbine. J Clin Psychiatry47: 508–510
313.
Saigusa T, Tuintra T, Koshikawa N, Cools A R (1999) High and low responders to novelty: effects of a catecholamine synthesis inhibitor on novelty-induced changes in behaviour and release of accumbal dopamine. Neuroscience88: 1153–1163
314.
Saito H, Matsumoto M, Togashi H, Yoshioka M (1996) Functional interaction between serotonin and neuronal systems: focus on in vivomicrodialysis studies. Jap J Pharmacol70: 203–225
315.
Sallinen J, Link R E, Haapalinna A, Viitamaa T, Kulatunga M, Sjoholm B, Macdonald E, Pelto-Huikko M, Leino T, Barsh G S, Kobilka B K, Scheinin M (1997) Genetic alteration of [.alpha]2C-adrenoceptor expression in mice: influence on locomotor, hypothermic and neurochemical effects of dexmedetomidine, a subtype-nonselective [.alpha]2-adrenoceptor agonist. Mol Pharmacol51: 36–46
316.
Sambunaris A, Hesselink J K, Pinder R, Panagides J, Stahl S M (1997) Development of new antidepressants. J Clin Psychiatry58: 40–53
317.
Sargent P A, Quested D J, Cowen P J (1998) Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors. Psychopharmacology140: 120–122
318.
Sari Y, Miquel M C, Brisorgueil M J, Ruiz G, Doucet E, Hamon M, Vergé D (1999) Cellular and subcellular localization of 5hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies. Neuroscience88: 899–915
319.
Schatzberg A F (1998) Noradrenergic versus serotonergic antidepressants: predictors of treatment response. J Clin Psychiatry59: 15–18
320.
Schilder E, Fink K, Molderings G J, Price G W, Duckworth M, Gaster L, Middlemiss D N, Zentner J, Likungu J, Göthert M (1997) Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto and heteroreceptors. Naunyn-Schmiedeberg's Arch Pharmacol356: 321–327
321.
Schmidt C J, Fadayel G M (1995) The selective 5-HT2A receptor antagonist, MDL 100, 907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol273: 273–279
322.
Schmidt C J, Sullivan C K, Fadayel G M (1994) Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3, 4-methylenedioxymethamphetamine. J Neurochem62: 1382–1398
323.
Schreiber R, De Vry J (1993) 5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of actions?Prog Neuro-Psychopharmacol Biol Psychiatry17: 87–104
324.
Schreiber R, Brocco M, Millan M J (1994) Blockade of the discriminative stimulus effects of DOI by MDL 100 907 and the ‘atypicaL’ antipsychotics, clozapine and risperidone. Eur J Pharmacol264: 99–102
325.
Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan M J (1995) [1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane]-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT)2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther273: 101–112
326.
Schweizer E, Thielen R J, Frazer A (1997) Venlafaxine: a novel antidepressant compound. Exp Opin Invest Drugs6: 65–78
327.
Sesack S R, Aoki C, Picket V M (1994) Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci14: 88–106
328.
Sharp T, Bramwell S R, Grahame-Smith D G (1989) 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol96: 283–290
329.
Sharp T, Umbers V, Gartside S E (1997) Effects of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br J Pharmacol121: 941–946
330.
Sibille E, Sarnyan Z, Benjamin D, Gal J, Baker H, Toth M (1997) Antisense inhibition of 5-hydroxytryptamine2A receptor induces an antidepressant-like effect in mice. Mol Pharmacol52: 1056–1063
331.
Silver H, Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on doubleblind, placebo-controlled study. Biol Psychiatry31: 698–704
332.
Silvestre J, Graul A, Castener J (1998) Sunepitron hydrochloride: anxiolytic antidepressant 5-HT1A autoreceptor agonist and alpha2-adrenoceptor antagonist. Drugs Future23: 161–165
333.
Siris S G (1991) Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull17: 75–97
334.
Siris S G, Bermanzohn P C, Mason S E, Shuwall M A (1994) Maintenance imipramine therapy for secondary depression in schizophrenia: a controlled trial. Arch Gen Psychiatry51: 109–115
335.
Skingle M, Sleignth A J, Feniuk W (1995) Effect of the 5-HT1D receptor antagonist, GR 127: 935, on extracellular levels of 5-HT in the guinea-pig frontal cortex as measured by microdialysis. Neuropharmacology34: 377–382
336.
Smith W T, Londborg P D, Glaudin V, Painter J R (1998) Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry155: 1339–1345
337.
Soares J C, Mann J J (1997) The anatomy of mood disorders – reviews of structural neuroimaging studies. Biol Psychiatry41: 86–106
Sorensen S M, Kehne J H, Fadayel G M, Humphreys T M, Ketteler H J, Sullivan C K, Taylor V L, Schmidt C J (1993) Characterization of the 5-HT2 receptor antagonist, MDL100907, as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther266: 684–691
340.
Sperling W L, Demling J (1997) New tetracyclic antidepressants. Drugs Today33: 95–102
341.
Srisurapanont M, Boonyanaruthee V (1997) Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect. J Med Assoc Thai80: 183–188
342.
Stanford I M, Lacey M G (1996) Differential actions of serotonin, mediated by 5-HT1B and 5-HT2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata neurons in vitro.J Neurosci16: 7566–7573
343.
Starke K, Göthert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev69: 864–989
344.
Starkey S J, Skingle M (1994) 5-HT1D as well as 5-HT1A autoreceptors modulate 5-HT release in the guinea pig dorsal raphe nucleus. Neuropharmacology33: 393–402
345.
Steffens D C, Krishnan K R R (1998) Structural neuroimaging and mood disorders: recent findings, implications for classification and future directions. Biol Psychiatry43: 705–712
346.
Suzuki M, Hurd Y L, Sokoloff P, Schwartz J-C, Sedvall G (1998) D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res779: 58–74
347.
Svensson T H, Bunney B S, Aghajanian G K (1975) Inhibition of both noradrenergic and serotonergic neurons in brain by the [.alpha]2-adrenergic agonist clonidine. Brain Res92: 291–306
348.
Svensson T H, Mathé J M, Andersson J L, Nomikos G G, Hildebrand B E, Marcus M (1995) Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5HT2 receptor and [.alpha]1-adrenoceptor antagonism. J Clin Psychopharmacol15: 11S–18S
349.
Szabadi E, Bradshaw C M, Boston P F, Langley R W (1998) The human pharmacology of reboxetine. Hum Psychopharmacol13: S3–S12
350.
Tanda G, Carboni E, Frau R, Di Chiara G (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?Psychopharmacology115: 285–288
351.
Tanda G, Frau R, Di Chiara G (1995) Local 5HT3 receptors mediate fluoxetine but not desipramine-induced increases of extracellular dopamine in the prefrontal cortex. Psychopharmacology119: 15–19
352.
Tang L, Todd R D, O'Malley K L (1994) Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther270: 475–479
353.
Tao R, Hjorth S (1992) [.alpha]2-adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. NaunynSchmiedeberg's Arch Pharmacol345: 137–143
354.
Tepper J M, Sun B C, Martin L P, Creese I (1997) Functional roles of dopamine D2 and D3 autoreceptors on nigrostriatal neurons analysed by antisense knockdown in vivo. J Neurosci17: 2519–2530
355.
Thase M E, Rush A J (1995) Treatment-resistant depression. Psychopharmacology92: 1081–1097
356.
Thorn L, Routledge C (1997) Comparative modulation of hippocampal 5-HT release by the 5-HT2C receptor antagonist SB 206553 and paroxetine. Br J Pharmacol120: 257P-257P
357.
Tian W N, Duzic E, Lanier S M, Deth R C (1993) Determinants of [.alpha]2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state. Mol Pharmacol45: 524–531
358.
Tingley F D, Schmidt A W, Rollema H, Clarke T, Lebel L L, Sprouse J S, Howard H R, Desai K, Schulz D W (1998) CP-291, 952, a high affinity 5-HT1D antagonist, enhances 5-HT neurotransmission in guinea pig brain. Am Soc Neurosci Abstr24: 438.16
359.
Tome M B, Isaac M T, Harte R, Holland C (1997) Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol12: 81–89
360.
Trendelenburg A U, Limberger, Starke K N (1993) Presynaptic [.alpha]2-autoreceptors in brain cortex: [.alpha]2D in the rat and [.alpha]2A in the rabbit. Naunyn-Schmiedeberg's Arch Pharmacol348: 35–45
361.
Trendelenburg A U, Starke K, Limberger N (1994a) Presynaptic [.alpha]2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices. Naunyn-Schmiedeberg's Arch Pharmacol350: 472–481
362.
Trendelenburg A U, Trendelenburg M, Starke K, Limberger N (1994b) Release inhibiting [.alpha]2-adrenoceptors at serotonergic axons in rat and rabbit brain cortex: evidence for pharmacological identity with [.alpha]2-autoreceptors. NaunynSchmiedeberg's Arch Pharmacol349: 25–33
363.
Trillat A C, Malagie I, Scearce K, Pons D, Anmella M C, Jacquot C, Hen R, Gardier A M (1997) Regulation of serotonin release in the frontal cortex and ventral hippocampus of homozygous mice lacking 5-HT1B receptors: in vivo microdialysis studies. J Neurochem69: 2019–2025
364.
Trillat A C, Malagie I, Mathe-Allainmat M, Anmella M C, Jacquot C, Langlois M, Gardier A M (1998) Synergic neurochemical and behavioral effects of fluoxetine and 5-HT1A receptor antagonists. Eur J Pharmacol357: 179–184
365.
Valerio A, Belloni M, Gorno ML, Tinti C, Memo M, Spano P (1992) Dopamine D2, D3 and D4 receptor mRNA levels in rat brain and pituitary during aging. Neurobiol Aging15: 713–719
366.
Van Veldhuizen M J A, Feenstra M G P, Heinsbroek R P W, Boer G J (1993) In vivomicrodialysis of noradrenaline overflow: effects of [.alpha]-adrenoceptor agonists and antagonists measured by cumulative concentration–response curves. Br J Pharmacol109: 655–660
367.
Westerink B H C, Kwint H F, De Vries J B (1996) The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci16: 2605–2611
368.
Westerink B H C, De Boer P, Kwint H F, De Vries J B, Kruse C G, Long S K (1998) Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol361: 27–33
369.
Wiech N L, Ursillo R C (1980) Acceleration of desipramine-induced decrease of rat corticocerebral [.beta]-adrenergic receptors by yohimbine. Commun Psychopharmacol4: 95–100
370.
Willins D L, Meltzer H Y (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a headtwitch response in rats. J Pharmacol Exp Ther282: 699–706
371.
Willins D L, Meltzer H Y (1998) Serotonin 5-HT2C agonists selectively inhibit morphine-induced dopamine efflux in the nucleus accumbens. Brain Res781: 291–299
372.
Willner P (1995) Dopaminergic mechanisms in depression and mania. In Bloom F E, Kupfer D J (eds), Psychopharmacology: the fourth generation in progress. Raven Press, New York, pp. 921–931
373.
Wolfersdorf M, Barg T H, Köning F, Leibfarth M, Grünewald I (1995) Paroxetine as an antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry28: 56–60
374.
Wurtman R J, Balcioglu A (1998) DOI, a 5-HT2 receptor agonist, increases both DA and 5-HT release in rat striatum. Am Soc Neurosci Abstr24: 541.5
375.
Yoshioka M, Matsumoto M, Numazawa R, Togashi H, Smith C B, Saito H (1995) Changes in the regulation of 5-hydroxytryptamine release by [.alpha]2-adrenoceptors in the rat hippocampus after longterm desipramine treatment. Eur J Pharmacol294: 565–570
376.
Zanardi R, Artigas F, Franchini L, Sforzini L, Gasperini M, Smeraldi E, Perez J (1997) How long should pindolol be associated with paroxetine to improve the antidepressant response?J Clin Psychopharmacol17: 446–450
377.
Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J (1998) Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol18: 441–446
378.
Zeng D, Lynch K R (1991) Distribution of [.alpha]2-adrenergic receptor mRNAs in the rat CNS. Mol Brain Res10: 219–225
